Lee Seung Jin, Kim Sang Geon
National Research Laboratory, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Mol Pharmacol. 2006 Jan;69(1):385-96. doi: 10.1124/mol.105.018465. Epub 2005 Oct 24.
Oltipraz, which has been extensively studied as a cancer chemopreventive agent, promotes phosphatidylinositol 3-kinase-mediated activation of CCAAT/enhancer binding protein-beta (C/EBPbeta). Activated p90 ribosomal S6-kinase-1 (RSK1) phosphorylates major transcription factors, including C/EBPbeta. This study examined whether oltipraz induces phosphorylation of C/EBPbeta at specific residues, and if so, whether RSK1 regulates C/EBPbeta phosphorylation by oltipraz for the GSTA2 gene transactivation. Subcellular fractionation and immunoblot analyses revealed that oltipraz treatment increased the level of C/EBPbeta phosphorylated at Ser(105) in the cytoplasm, which translocated to the nucleus for DNA binding in rat H4IIE cells. Immunoprecipitation-immunoblot, chromatin-immunoprecipitation, and specific mutation analyses revealed that Ser(105)-phosphorylated C/EBPbeta recruited the cAMP response element-binding protein binding protein for histone acetylation and transactivation of the GSTA2 gene. The role of RSK1 in Ser(105)-phosphorylation of C/EBPbeta by oltipraz and its gene transactivation was evidenced by transfection experiments with dominant-negative mutants of RSK1. In mouse Hepa1c1c, human HepG2 cells, and rat primary hepatocytes, oltipraz induced phosphorylation of C/EBPbeta at Thr(217), Thr(266), and Ser(105), respectively, via RSK1. The experiment using small-interference RNA of RSK1 confirmed the essential role of RSK1 in the gene expression. Inhibition of PI3-kinase activity prevented oltipraz-inducible Ser(105)-phosphorylation of rat C/EBPbeta. Oltipraz treatment led to increases in the catalytic activity and nuclear translocation of RSK1, which was abrogated by PI3-kinase inhibition. In summary, oltipraz induces the phosphorylation of rat C/EBPbeta at Ser(105) (functionally analogous Thr(217/266) in mouse and human forms) in hepatocytes, which results in cAMP response element-binding protein-binding protein (CBP) recruitment for the GSTA2 gene transactivation, and the specific C/EBPbeta phosphorylation is mediated by RSK1 downstream of PI3-kinase.
奥替普拉作为一种癌症化学预防剂已得到广泛研究,它能促进磷脂酰肌醇3激酶介导的CCAAT/增强子结合蛋白β(C/EBPβ)激活。活化的p90核糖体S6激酶1(RSK1)可使包括C/EBPβ在内的主要转录因子磷酸化。本研究检测奥替普拉是否诱导C/EBPβ在特定残基处磷酸化,若如此,RSK1是否通过奥替普拉调节C/EBPβ磷酸化以实现谷胱甘肽S转移酶A2(GSTA2)基因的反式激活。亚细胞分级分离和免疫印迹分析显示,奥替普拉处理可增加大鼠H4IIE细胞胞质中Ser(105)位点磷酸化的C/EBPβ水平,其转位至细胞核进行DNA结合。免疫沉淀-免疫印迹、染色质免疫沉淀及特异性突变分析显示,Ser(105)磷酸化的C/EBPβ募集环磷酸腺苷反应元件结合蛋白结合蛋白以进行组蛋白乙酰化及GSTA2基因的反式激活。用RSK1显性负性突变体进行的转染实验证明了RSK1在奥替普拉诱导的C/EBPβ Ser(105)磷酸化及其基因反式激活中的作用。在小鼠Hepa1c1c、人HepG2细胞及大鼠原代肝细胞中,奥替普拉分别通过RSK1诱导C/EBPβ在Thr(217)、Thr(266)和Ser(105)位点磷酸化。使用RSK1小干扰RNA的实验证实了RSK1在基因表达中的重要作用。抑制PI3激酶活性可阻止奥替普拉诱导的大鼠C/EBPβ Ser(105)磷酸化。奥替普拉处理导致RSK1的催化活性增加及核转位,而PI3激酶抑制可消除这种作用。总之,奥替普拉可诱导肝细胞中大鼠C/EBPβ在Ser(105)(在小鼠和人形式中功能类似的Thr(217/266))位点磷酸化,这导致募集环磷酸腺苷反应元件结合蛋白结合蛋白(CBP)以实现GSTA2基因的反式激活,且特定的C/EBPβ磷酸化由PI3激酶下游的RSK1介导。